Table 1.

Summary of histopathological findings in C9ORF72-positive ALS/FTD cases and controls

Region and caseCase informationRAN inclusions
C9 EXPAgeSex/racePMDDXGPPAPRGRGA
Hippocampus
 1+59F/W4ALS+++++++++
 2+42M/W10A/F++++NANANA
 3+74F/W16FTD++++++*+++*+++
 4+45M/W3ALS+++++++
 5+82F/W17FTD++++++++
 6+86F/W10A/F+++++
 776M/W7ALS
 855M/W7.5ALSNANANA
 960M/W16CONNANANA
 1081M/W6FTDNANA
 1183M/W17FTD
 1277M/W16CON
Motor cortex
 1+59F/W4ALS+++++++
 2+42M/W10A/F++++++
 776M/W7ALS
 855M/W7.5ALS
 960M/W16CON
Spinal cord
 2+42M/W6A/F+
 13+53M/W10ALS+
 14+55F/W?A/F+
 776M/W7ALS
 855M/W7.5ALS
 960M/W16CON
 1564F/W0ALS
 1679M/W33ALS
 1779M/W10ALS
  • —, no inclusions; +, occasional; ++, moderate; +++, numerous inclusions; *, variable staining from section to section; A/F, ALS/FTD; CON, control; DX, diagnosis; F, female; M, male; NA, not available; PMD, postmortem interval; W, white/Caucasian. The apparent differences in the frequencies of the various inclusions may reflect differences in protein conformation and epitope availability or differences in the affinities of these antibodies.